Analysts Set Opus Genetics, Inc. (NASDAQ:IRD) Price Target at $9.25

Opus Genetics stock earns 'Moderate Buy' rating from analysts

Mar. 22, 2026 at 8:54am

Got story updates? Submit your updates here. ›

Shares of Opus Genetics, Inc. (NASDAQ:IRD) have earned an average recommendation of 'Moderate Buy' from the eleven research firms that are presently covering the firm, according to Marketbeat.com. The average 1 year price objective among brokers that have covered the stock in the last year is $9.33.

Why it matters

Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The 'Moderate Buy' rating and $9.25 average price target from analysts indicate optimism about the company's future prospects.

The details

The analysts' recommendations for Opus Genetics stock include one sell rating, nine buy ratings, and one strong buy rating. Oppenheimer initiated coverage on Opus Genetics with an 'outperform' rating and a $10.00 price target, while Wall Street Zen upgraded the stock from a 'sell' rating to a 'hold' rating. BTIG Research also upped its target price on Opus Genetics from $7.00 to $12.00 and maintained a 'buy' rating.

  • On Monday, March 16th, CEO George Magrath sold 24,438 shares of the firm's stock at an average price of $5.21.
  • On Monday, December 29th, Director Cam Gallagher acquired 83,000 shares of Opus Genetics stock at an average price of $1.97 per share.

The players

Opus Genetics, Inc.

A clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders.

George Magrath

The Chief Executive Officer of Opus Genetics.

Cam Gallagher

A Director at Opus Genetics.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.